<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769171</url>
  </required_header>
  <id_info>
    <org_study_id>11647</org_study_id>
    <nct_id>NCT00769171</nct_id>
  </id_info>
  <brief_title>Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)</brief_title>
  <acronym>DRAGON</acronym>
  <official_title>A Prospective, Randomized, Double-blinded, Multi-center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidazole 500mg Every 12h for the Treatment of Patients With Complicated Intra-abdominal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of intravenous administration
      Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the
      treatment of patients with complicated intra abdominal infections. In view of the fact that
      intra abdominal infections are typically polymicrobial and are often treated empirically, the
      selected antibacterial agent must cover the likely spectrum of bacterial pathogens.
      Combination antibiotics therapy has been widely used with great success.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>After 10-14 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and bacteriological response</measure>
    <time_frame>During 3-5days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological and radiological response</measure>
    <time_frame>After 10-14 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response at the TOC visit in patients with bacteriological proven intra abdominal infection</measure>
    <time_frame>After 10-14 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality attributable to intra abdominal infection</measure>
    <time_frame>13-28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>Infection, Intra-abdominal</condition>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelox (Moxifloxacin, BAY12-8039)</intervention_name>
    <description>Moxifloxacin 400 mg every 24 h</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone + Metronidazole</intervention_name>
    <description>Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized males or females &gt;/= 18 years of age

          -  Expected duration of treatment with intravenous antibiotics in hospital is anticipated
             to be &gt;/= 3 full days but not exceeding 14 days

          -  Ability to provide written informed consent

          -  Confirmed or suspected intra abdominal infection through surgical procedure or
             Radiological evidence. For suspected intra abdominal infection, The patient must be
             scheduled for a surgical procedure

        Exclusion Criteria:

          -  Known hypersensitivity to fluoroquinolones, or other quinolones, and/or to beta
             lactams antibiotic drugs, or metronidazole or any of the excipients. History of tendon
             disease/disorder related to quinolone treatment

          -  Known congenital or documented acquired QT prolongation; uncorrected hypokalemia;
             clinically relevant bradycardia; clinically relevant heart failure with reduced left
             ventricular ejection fraction; previous history of symptomatic arrhythmias.
             Concomitant use of any of the following drugs, reported to increase the QT interval:

          -  Known severe end stage liver disease (Child Pugh C)

          -  Systemic antibacterial therapy for more than 24 h within 7 days of enrollment

          -  Indwelling peritoneal catheter, Pre existing ascites and presumed spontaneous
             bacterial peritonitis

          -  All pancreatic processes including pancreatic sepsis, peripancreatic sepsis, or an
             intra abdominal infection secondary to pancreatitis

          -  Traumatic perforation of the upper gastrointestinal tract (stomach, duodenum) or
             perforated peptic ulcer if duration of perforation is &lt; 24 h or if operated on within
             24 h of perforation

          -  Traumatic perforation of the small or large bowel if duration of perforation is &lt; 12 h
             or if operated on within 12 h of perforation

          -  Transmural necrosis of the intestine due to acute embolic, thrombotic, or obstructive
             occlusions

          -  Acute cholecystitis with infection confined to the gallbladder unless there is
             evidence of an abscess or necrotic tissue or purulent exudate surrounding the
             gallbladder indicating a transition of bacteria and the inflammatory process into the
             abdominal cavity

          -  Early acute or suppurative, nonperforated appendicitis unless there is evidence of an
             abscess or peritoneal fluid containing leukocytes and micro organisms suggestive of
             regional contamination

          -  Infections originating from the female genital tract. Perinephric infections

          -  Severe, life threatening disease with a life expectancy of &lt; 48 h or APS and APACHE
             scores of &gt; 35, Known rapidly fatal underlying disease (death expected within 6
             months)

          -  Neutropenia (neutrophil count &lt; 1,000/microliter) caused by immunosuppressive therapy
             or malignancy

          -  Patients known to have AIDS or HIV seropositives who are receiving HAART
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uijeongbu</city>
        <state>Kyonggi-do</state>
        <zip>480-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terengganu</city>
        <zip>20400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaoshiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>70428</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer HealthCare AG</organization>
  </responsible_party>
  <keyword>Complicated Intra-Abdominal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

